Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameBayzed Health
Stock Code02609
Company Full NameBayzed Health Group Inc
Industry醫療保健
Principal Activities公司是中國領先的主要從事投資及提供醫療相關服務的腫瘤醫療集團。
Listing Date2025-06-23
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市豐臺區萬豐路68號銀座和諧廣場寫字樓1505室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.bayzedhealthcare.com/
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 4.22 / shares
Offer Price RangeFinal offer price only, no range
Lot Size600 shares
Entry ThresholdHK$ 2,532
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares133,105,800 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share26.5%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 561,706,476

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 600 HK$ 2,532
2 lots 1,200 HK$ 5,064
3 lots 1,800 HK$ 7,596
4 lots 2,400 HK$ 10,128
5 lots 3,000 HK$ 12,660
6 lots 3,600 HK$ 15,192
7 lots 4,200 HK$ 17,724
8 lots 4,800 HK$ 20,256
9 lots 5,400 HK$ 22,788
10 lots 6,000 HK$ 25,320
15 lots 9,000 HK$ 37,980
20 lots 12,000 HK$ 50,640
25 lots 15,000 HK$ 63,300
30 lots 18,000 HK$ 75,960
35 lots 21,000 HK$ 88,620
40 lots 24,000 HK$ 101,280
45 lots 27,000 HK$ 113,940
50 lots 30,000 HK$ 126,600
75 lots 45,000 HK$ 189,900
100 lots 60,000 HK$ 253,200
125 lots 75,000 HK$ 316,500
150 lots 90,000 HK$ 379,800
175 lots 105,000 HK$ 443,100
200 lots 120,000 HK$ 506,400
225 lots 135,000 HK$ 569,700
250 lots 150,000 HK$ 633,000
500 lots 300,000 HK$ 1,266,000
750 lots 450,000 HK$ 1,899,000
1,000 lots 600,000 HK$ 2,532,000
1,250 lots 750,000 HK$ 3,165,000
1,500 lots 900,000 HK$ 3,798,000
1,750 lots 1,050,000 HK$ 4,431,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
2,000 lots 1,200,000 HK$ 5,064,000
2,250 lots 1,350,000 HK$ 5,697,000
2,500 lots 1,500,000 HK$ 6,330,000
5,000 lots 3,000,000 HK$ 12,660,000
7,500 lots 4,500,000 HK$ 18,990,000
11,092 lots 6,655,200 HK$ 28,084,944

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 4.59B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 294.24 million
Listing ExpensesTo be extracted
Listing Expenses / Funds Raised~14.7%
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 6.0
First Day OpenHK$ 5.25
First Day Change42.18%
First Day Volume21787300.0
First Day Turnover117245000.0
Use of Proceeds
1、約35.7%(或222.8百萬港元)用于持續強化我們的腫瘤全周期醫療服務; 2、約30.6%(或191.0百萬港元)用于在有適當機會出現時在符合以下標準的新市場收購醫院:(i)人口規模較大;(ii)經濟發展達到一定水平;及(iii)由于專科腫瘤領域的醫療資源相對稀缺而存在需求缺口的省份及╱或城市; 3、約15.3%(或95.4百萬港元)用于擴展醫院管理業務,包括但不限于增強信息系統及平臺以及招聘運營管理專業人員; 4、約10.2%(或63.7百萬港元)用于升級信息技術基礎設施及╱或系統,以提升醫療服務提供能力以及運營及管理效率; 5、約8.1%(或50.7百萬港元)用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
招银国际融资有限公司 CE AVM940
Overall Coordinators (1)
招银国际融资有限公司 CE AVM940
Joint Bookrunners (1)
招银国际融资有限公司 CE AVM940
Joint Lead Managers (2)
招银国际融资有限公司 CE AVM940 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 149,041,116 HKD — 26.50% — 6 months 2025-12-23

Directors & Management

PositionChinese nameEnglish Name
Chairman趙永凱—
Company Secretary姚樂,方希琳—
No director data available.

Major Shareholders

Major Shareholders & HoldingsBayway Fund L.P.(51.75%),上海正闔盛企業管理合伙企業(有限合伙)(8.27%),Xuxi Holding Ltd.(7.28%),上海晟荏企業管理合伙企業(有限合伙)(6.88%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The IPO of 佰泽医疗 (02609) saw an oversubscription ratio of 25.92x, indicating robust retail demand. Thanks to reallocation from the international tranche, the overall hit rate reached 40.16%, allowing a high proportion of applicants to receive shares and underscoring a buyer-friendly allocation. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

The A-tail applied for 600,000 shares (1,000 lots) with an expected allocation of just 0.125 lots, while the B-head required only a slightly larger application of 750,000 shares (1,250 lots) but offered an expected 0.5 lots—four times the A-tail allocation. This stepwise jump reveals an inefficient tier structure where a small increase in capital significantly boosts expected shares, potentially concentrating applications at B-head despite fractional expected lots. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice. Broker fee structures vary and actual costs may differ.)

Demographics

Mainland China participation dominated at 75.7%, signaling strong cross-border interest in this offering. The investor base skewed male (67.2%) with an average age of 42.8, typical of experienced, middle-aged participants. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Bayzed Health (02609) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect